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Sjögren’s Syndrome (SS) is considered a multisystemic
chronic disorder, which is characterized by a lymphocytic
infiltration of exocrine glands and autoantibodies
production. Aim: Several studies have demonstrated
increased incidence of Lymphoma in SS patients. Our
study tries to determine this relation. Study design:
Transversal cohort. Material and Method: Patients with
Sicca’s Syndrome from the Stomathology service, Santa
Casa de Misericórdia Hospital, in Sao Paulo, ENT
Department, from July 1999 to April 2002. Results: Out
of 39 patients, 24 were diagnose as SS. Ages ranged
from 19 to 83 years old, with predominance of women
(69.7%). Time between the first symptoms and SS
diagnosis were variable, ranging within 3.77 years. None
of the analyzed patients developed lymphoma.
Conclusion: Both SS early diagnosis and the increased
risk of lymphoma’s development in those patients are
important, reason why long-term follow-up is essential.
We observed that our findings were different from those
in the literature. We did not detect any cases of
lymphoma in our patients.
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INTRODUCTION
Sjögren’s syndrome (SS) is considered a chronic,
multisystemic affection that is characterized by exocrine gland
dysfunction, systemic multiple organ abnormality and
serological hyperreactivity. It presents two different forms:
the primary form, characterized by xerostomia and
xerophthalmia, and the secondary form in which at least
one of these two symptoms is associated with connective
tissue disease.
SS is characterized by lymphocytic infiltration in tissues
and the production of autoantibodies. The etiology is not
well defined but genetic, hormone and environmental factors
may be involved 1. Approximately 90% of the patients with
SS are female subjects, aged between 40 and 50 years, but
it has also been found in children 2. The patients with
enlarged salivary glands are constantly a great problem in
SS. Persistent gland involvement in these subjects are of
concern owing to the risk of transformation in Non-Hodgkin
lymphoma. They are low-grade B cell lymphomas and they
may have similar characteristics to the lymphomas that are
developed in other mucosa-associated lymphoid tissues
(MALT), which include the stomach, thyroid and liver 3.
Malignant lymphoma was primarily described in
patients with SS in 1963 4. Subsequently, many described
cases sustained the association between lymphoma and
Sjögren’s syndrome 5, 6 and recognized Non-Hodgkin
Malignant Lymphoma (NHML) as the main complication of
the disease progression 7. The estimated risk of NHML was
44 times higher than in the normal population 7.
According to Sreebney & Broid 19878, patients with
SS present higher risk of developing malignant lymphomas
owing to the correlation between immune deficits and
lymphoid system diseases.
The factors implied in the genesis of lymphoma
include deregulation of mechanisms that lead to apoptosis,
B cell hyperstimulation, and participation of infectious agents.
Polyclonal lymphoproliferation that characterizes SS may be
transformed into monoclonal and them into malignancy 9.
Among the considered infectious agents, there seems to be
a correlation between hepatitis C virus and SS 10.
The concept of MALT lymphoma suggests that these
tumors correspond to stages of post-follicular cell
differentiation and normally they are present in sites of
chronic antigen stimulation firing by persistent infections or
autoimmune processes or both 11.
Salivary MALT lymphomas may be of low grade and
indolent 12, 13. Some patients survive years without any
evidence of systemic disease after the diagnosis and many
salivary lymphoepithelial lesions that have evidence of
monoclonality do not progress to definite manifestations of
lymphoma 13. Studies have shown that between 40 to 80%
of the salivary lymphoepithelial lesions may have
monoclonal proliferation 14.
Five percent of the patients with primary SS
occasionally develop B cell lymphoma 15.
According to Zufferey et al.16, the interval between
diagnosis of SS and onset of lymphoma normally ranges from
4 to 12 years.
MATERIAL AND METHOD
We carried out a prospective clinical and laboratory
cross-sectional study with 39 patients complaining of
xerostomia in the period between July 1999 and April 2002,
in the ambulatory of Stomathology, Department of
Otorhinolaryngology, Santa Casa de Misericórdia de Sao Paulo.
As inclusion criteria, all patients presented initial complaint
of dry mouth (xerostomia). There was no exclusion of
patients that were under use of any type of medication, nor
patients that had associated diseases.
Patients were classified as having Sjögren’s syndrome
based on GECE criteria 17-20. The criteria included 6 items
out of which 4 should be present to define the classification.
RESULTS
A sequential sampling was made with 39 patients, all
with xerostomia, and out of the total, 24 were classified as
having SS (they complied with 4 out of 6 criteria) compared
to 15 patients that were not classified as having Sjögren’s
syndrome (NSS) (Tables 1 and 2). The age of the patients
ranged from 19 to 83 years. We observed that among the
15 patients that did not have SS the mean age was 53.67
years and among the 24 holders of SS the mean age was
61.29 years. The time interval between beginning of
xerostomia and diagnosis of SS ranged from 6 months to 13
years, mean time of 3.77 years.
As to gender, in our sample we found predominance
of female patients in relation to male patients. Out of the
total number of male patients only 16.7% had SS, whereas
69.7% of female patients had SS.
In our sample, we did not observe development of
lymphoma in any of the assessed patients.
DISCUSSION
Low prevalence of primary Sjögren’s syndrome in the
general population, estimated to be 0.2 to 1.4% 21, combined
with the estimated risk of MALT lymphoma, reaching 6.4
cases per 1,000 per year 7 emphasizes the limited area of
study of the disease owing to reduced number of patients
22.
Lymphomas affect many different extranodal sites,
normally in the gastrointestinal tract, appearing in sites of
chronic inflammatory disease or autoimmune diseases, such
as Hashimoto thyroiditis, Sjögren’s syndrome, Helicobacter
Pylori inducing chronic gastritis, etc.23. The lesion tends to
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remain stable for prolonged periods of time without
dissemination, and it also tends to involve other mucous
organs 24.
A recent report informed that MALT lymphoma
amounts to 46 to 56% of malignant lymphomas that were
developed in patients with SS 23,25.
The occurrence of MALT lymphoma in the
gastrointestinal tract is less common in patients that have
preexisting SS 26.
According to Tomani et al. (2002)26, 5 patients
presented MALT lymphoma at the same time in which
primary SS was diagnosed or they developed lymphoma
after the diagnosis of SS. In 3 patients, Sjögren’s syndrome
was diagnosed 1, 3 and 10 years, respectively, before the
diagnosis of MALT lymphoma. In the other 2 cases, SS and
MALT lymphoma were diagnosed simultaneously.
Consequently, for these 5 patients, the time interval
between diagnosis of SS and diagnosis of MALT lymphoma
was 2.8 years.
Royer et al. (1997)27 reported 9 patients with MALT
lymphoma associated with SS and in 5 the parotid gland
was the most frequent initial site, followed by stomach, lung,
oral mucosa and lymphoid nodes.
Sutcliffe et al., (1998)12, in a retrospective study with
72 patients with primary SS that were classified according to
the European criteria of Vitalli et al., followed up for a period
of 10 years, had 5 patients that developed MALT Non-
Hodgkin lymphoma (prevalence of 7%) and they were all
women. As to lymphoma diagnosis, the age was 63 years
and the mean disease time was 14 years. According to the
study, the likelihood of MALT lymphoma development was
18% after 20 years from onset of the disease.
Sutcliffe et al. (1998)12 observed the presence of
extraglandular manifestations as opposed to Sicca Syndrome
alone, which does not differentiate the lymphoma group,
because both groups have high frequency of extraglandular
involvement.
In their study, Voulgarelis et al. (1999)22 suggested
that salivary glands in patients with SS are the most commonly
affected initial sites in the transformation of neoplastic B
cells, but other MALT sites, such as bone marrow and
lymphoid nodes were also identified as initial sites of
malignant transformation.
Recent studied identified predictive factors for the
occurrence of Non-Hodgkin lymphoma in patients with SS:
parothydomegalia 7,27, low doses of parotid radiation 27,
splenomegalia 27,28, lymphadenopathy 7,27,28, presence of
urinary or serum monoclonal component 27,28, reduction of
polyclonal serum immunoglobulin 27,28, reduction of
rheumatoid factor titers 28, leukopenia 28 and purpura 28. In
our study, we did not observe any of the above mentioned
manifestations.
According to Voulgarelis et al. (2001)28, the
presence of mixed monoclonal cryoglobulin proves to
be the most significant risk for development of
lymphoma.
In our study, what attracted our attention was the
fact that even though all SS patients had been followed up
to present, we have not found any clinical or laboratory
indication of lymphoma development, contrarily to the
literature, which makes us pose the following question: would
the pathology behave differently in Brazil?
CONCLUSION
As years go by, we have observed an increasingly
higher number of patients with Sjögren’s syndrome owing
to the redefinition of classification criteria and the new
techniques that favor more precise diagnoses. We emphasize
the importance of SS diagnosis and the risk of malignant
development with time, which means that long-term follow-
up is absolutely mandatory in such patients. In our study,
patients have been followed up to present and there have
been no clinical or laboratory manifestations for the diagnosis
of lymphoma.
REFERENCES
1. Baccaglini L, Pillemer SR, Baum BJ. Sjögren’s Syndrome: possible
pathogenetic mechanism involving somatostatin. Oral Diseases
2000; 6: 264-6.
2. Fox PC. Management of Dry Mouth. Dent Clinics of North America
1997; 41: 863-75.
3. Field EA, Longman LP, Bucknall R, Kaye SB, Higham SM, Edgar WM.
The establishment of a xerostomia of a clinic: a prospective study.
British Journal of Oral and Maxillofacial Surgery 1997; 35: 96-103.
4. Bunim JJ, Talal N. Development of malignant lymphoma in the course
of Sjögren’s Syndrome. Trans Assoc Am Physicians 1963; 76: 45-56.
5. Hornbacker JH, Foster EA, Williams, GS, Davis JS. Sjögren’s
Syndrome and nodular reticulum - cell sarcoma. Arch Interm
Med 1966; 118: 449-52.
6. Talal N, Sokoloffl, Barth WF. Extrasalivary lymphoid abnormalities
in Sjögren’s Syndrome (reticulum-cell sarcoma, “pseudolymphoma”
macroglobulimemia). Am J Med 1967; 43: 50-65.
7. Kassam SS, Thomas TL, Mousopoulos HM, Hoover R, Kimberly RP,
Budman DR et al.  Increased risk of lymphoma in sicca syndrome.
Ann Intern Med 1978; 89: 888-92.
8. Sreebny LM, Broich G. Xerostomia (Dry Mouth). The Salivary
System. 1987; 9: 179-202.
9. Anaya LM, McGuff HS, Banks PM, Tala N. Clinical-pathological
factors relating malignant lymphoma with Sjögren’s Syndrome.
Semin Arthritis Rheum 1996; 25: 337-46.
10. Youinou P et al. CD-5 expressing B lymphocytes in the blood and
salivary glands of patients with Sjögren’s Syndrome. J Autoimmum
1988; 1: 185-94.
11. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated
lymphoid tissue: a distinctive type of B-cell lymphoma. Cancer
1983; 52: 1410-6.
12. Sutcliffe N, Inabc M, Speight P, Isenberg D. Predictors of lymphoma
development in primary Sjögren’s Syndrome. Semin Arthritis Rheum
1998; 28: 80-7.
13. Sutcliffe N, Smith C, Speight P. Isenberg D. Mucosa-associated
lymphoid tissue lymphomas in two patients with rheumatoid arthritis
on second-line agents, and secondary Sjögren’s Syndrome. Rheum
200; 39: 185-8.
345
BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY 71 (3) PART 1 MAY/JUNE 2005
http://www.rborl.org.br  /  e-mail: revista@aborlccf.org.br
14. Jordan RCK, Odell E, Speight P. B-cell monoclonality in salivary
lymphoepithekial lesions. Oral Oncol 1996; 32 B: 38-44.
15. Haga HJ. Clinical and immunological factors associated with low
lachrymal and salivary flow rate in primary Sjögren’s Syndrome.
Semin Arthritis Rheum. The Journal of Rheumatology 1999; 26:
604-7.
16. Zufferey P, Meyer OC, Grossin M, Kahn MF. Primary Sjögren’s
Syndrome (SS) and malignant lymphoma. A retrospective cohort
study of 55 patients with SS. Scand J Rheumatol 1995; 24: 342-5.
17. Vitali C et al.  Preliminary criteria for the classification of Sjögren’s
Syndrome. Result of a prospective Concerted Action Supported by
European Community. Arthritis and Rheumatism 1993; 36: 340-7.
18. Vitali C, Moutsopoulos H. M, Bombardieri S. The European
Community Study Group on Diagnostic Criteria for Sjögren’s
Syndrome. Sensitivity and specificity of tests for ocular and oral
involvement in Sjögren’s Syndrome. Annals of the Rheumatic
Diseases 1994; 53: 637-47.
19. Vitali C et al. Assessment of the European classification criteria
Sjögren’s Syndrome in series of clinically defined cases: case results
of a prospective multicentre study. Ann Rheum Dis 1996; 55:
116-21.
20. Vitali C, Bombardieri S. The diagnosis of Sjögren’s Syndrome;
definition and validation of classification criteria for this disorder.
Ann Med Interne 1998; 149: 12-6.
21. Dafni U, Tzioufas AG, Skoupouli FN, Moutsopoulos HM. Prevalence
of Sjögren’s Syndrome in a closed rural community. Ann Rheum
Dis 1997; 56: 521-5.
22. Vougarelis M, Dafni U, Isenberg DA, Moutsopoulos HM. AND
Members of European Concerted Action on Sjögren’s Syndrome.
Malignant lymphoma in Sjögren’s Syndrome. Arthis & Rheum 1999;
42: 1765-72.
23. Thieblemont C, Bastion Y, Berger F et al.  Mucosa-associated
lymphoid tissue gastrointestinal and nongastrointestinal lymphomas
behavior: analysis of 108 patients. J Clin Oncol 1997; 15: 1624-
30.
24. Araki K, Kubota Y, Lijima Y et al.  Indolent behave of low-grade
B-cell lymphoma of mucosa-associated lymphoma tissue involved
in salivary glands, renal sinus and prostate. Scand J Urol Nephol
1998; 32: 234-6.
25. Royer B, Cazals-Haterm D, Sibilia J et al.  Lymphomas in patients
with Sjögren’s Syndrome are marginal zone B-cell neophasma,
arise in diverse extranodal sites, and are not associated with viruses.
Blood 1997; 90: 766-75.
26. Tomani H, Matoba M, Yokota H, Higashi K, Yamamoto I, Sugai S.
Mucosa-associated lymphoid tissue lymphoid in Sjögren’s Syndrome:
Initial and follow-up imaging features AJR 2001; 79: 485-9.
27. Royer B, Cazals-Hatem D, Sibilia J et al. Lymphoma in patients
with Sjögren’s Syndrome are marginal zone B-cell neophasms,
arise in diverse extranodal and nodal situ, and are not associated
with viruses. Blood 1997; 90: 766-75.
28. Vougarelis M, Moutsopoulos HM. Malignant lymphoma in primary
Sjögren’s Syndrome. IMAJ 2001; 3: 761-6.
